Further studies are warranted to elucidate the clinical and/or biological significance of uncommon mutations, doublet non-p.L858R missense mutations of EGFR, and concomitant kinase-impaired BRAF mutations in lung cancers. This evidence concerns the gene BRAF and lung cancer.